New international media company to spotlight the rapidly evolving psychedelic medicine, mental health, and alternative healthcare sectors
Psychedelics.Media today announced the official launch of its public beta platform, marking the debut of a new global media business dedicated to covering the rapidly emerging psychedelic medicine, mental health, and alternative healthcare sectors.
Officially entering beta on May 4, 2026, the platform aims to provide professional journalism, market intelligence, multimedia storytelling, and international industry coverage focused on psychedelic therapies, mental health innovation, biotechnology, neuroscience, policy reform, clinical research, and evolving models of alternative healthcare around the world.
The newly launched platform, available at www.Psychedelics.Media, will publish a broad mix of content including:
• Breaking industry news
• Executive interviews and founder profiles
• Clinical trial and biotechnology coverage
• Market analysis and investor insights
• Regulatory and legislative developments
• Podcasts and video media
• Long form features and investigative journalism
• Educational content and industry explainers
• Short form documentary content exploring science, culture, innovation, and patient experiences
A major editorial focus of the platform will be tracking the global evolution of psychedelic legislation, prescribing pathways, scientific research programs, and emerging treatment models across key international jurisdictions.
Countries including Australia, New Zealand, Thailand, Canada, Switzerland, Germany, Portugal, the Netherlands, the United Kingdom, and parts of the United States are increasingly becoming focal points for psychedelic policy reform, clinical trials, mental health innovation, and pharmaceutical development.
Australia, in particular, became one of the first countries in the world to formally reschedule psilocybin and MDMA for limited psychiatric prescribing through authorised psychiatrists in 2023, a milestone widely regarded as one of the sector’s most significant regulatory developments to date.
Across Europe and the United Kingdom, momentum continues to build around ketamine assisted psychotherapy, psilocybin research, MDMA assisted therapy trials, and broader discussions surrounding next generation psychiatric treatments and mental healthcare reform.
Meanwhile, growing research activity and policy discussions are also beginning to emerge throughout Asia, including Thailand, where increasing attention is being placed on psychedelic science, mental health research, and plant based therapeutic innovation.
The launch also comes amid renewed international attention on psychedelic research following recent commentary and policy discussions linked to senior United States political figures advocating for expanded scientific research into compounds including ibogaine and psilocybin, particularly in areas relating to mental health, addiction, trauma, and veteran care.
The platform says its mission is to help readers better understand how psychedelic medicine and alternative healthcare systems are evolving across different legal, scientific, cultural, and commercial environments worldwide.
“Psychedelic medicine is moving from the fringe into serious scientific, medical, and public policy discussions around the world,” said Gary Mackenzie, Editor of Psychedelics.Media and host of TheDispensaryPodcast.com, a podcast covering the global cannabis, psychedelics, and emerging alternative healthcare industries.
“We’re seeing governments, researchers, clinicians, biotechnology companies, and investors increasingly engaging with this sector in meaningful ways. Different countries are moving at different speeds, with different regulatory models and cultural perspectives, and we believe there is a strong need for an independent global media platform dedicated to covering that evolution professionally, responsibly, and with a genuinely international outlook.”
The company plans to initially operate as a digital first publication during its beta phase, with expanded newsletters, podcasts, documentary series, industry reports, and strategic media partnerships expected throughout 2026.
To mark the public beta launch, Psychedelics.Media confirmed that founding subscribers who join during the initial rollout phase will receive 12 months complimentary access to upcoming premium digital magazine content and subscriber publications.
Psychedelics.Media is part of a broader ecosystem of psychedelic education, media, research, and industry initiatives, with future collaborations expected across professional networks, conferences, research communities, and global directory platforms.
The beta platform is now live and accepting contributors, media partners, podcast guests, documentary collaborators, and industry submissions.
